NCT02501811View on ClinicalTrials.gov

Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

June 25, 2020

Study Completion Date

July 22, 2020

Conditions
Ischemic Cardiomyopathy
Interventions
BIOLOGICAL

Mesenchymal Stem Cells (MSC)

15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)

BIOLOGICAL

c-kit+ cells

15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)

BIOLOGICAL

Placebo (Plasmalyte A)

15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure)

Trial Locations (7)

32610

University of Florida-Department of Medicine, Gainesville

33101

University of Miami-Interdisciplinary Stem Cell Institute, Miami

40202

University of Louisville, Louisville

46202

Indiana Center for Vascular Biology and Medicine, Indianapolis

55407

Minneapolis Heart Institute Foundation, Minneapolis

77030

Texas Heart Institute, Houston

94305

Stanford University School of Medicine (Falk Cardiovascular Research Center), Stanford

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

The University of Texas Health Science Center, Houston

OTHER

NCT02501811 - Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure | Biotech Hunter | Biotech Hunter